new currency usa, Featured

Hailian Jinhui invested 20 million yuan to set up an auto parts company in Wuhu. According to the enterprise search APP, Wuhu Hailian Jinhui Auto Parts Co., Ltd. was established recently, with the legal representative of Wang Weichao and the registered capital of 20 million yuan. Its business scope includes: manufacturing of auto parts and accessories; Mold manufacturing; Sales of metal materials; New material technology research and development, etc. Enterprise investigation shows that the company is indirectly wholly-owned by Hailian Jinhui.Chief Cabinet Secretary of Japan: Short-term data show that enterprises have a strong willingness to invest.The net outflow of the main market exceeded 10 billion.

It is reported that Baidu and Geely are taking the transfer process to pay the social security arrears for employees of Extreme Vietnam in November. According to media reports, on the evening of December 12, the CEO of Extreme Vietnam Xia Yiping and Geely and Baidu held a closed meeting. After several rounds of communication, Baidu and Geely are taking the transfer process to pay the arrears of social security for employees in November. Shareholders Geely and Baidu set up an emergency team to participate remotely. In response to this news, Baidu and Geely did not comment. (Sina Technology)The weighted share price index of Taiwan Stock Exchange opened 0.2% lower at 23,002.37.The CSI convertible bond index opened lower by 0.03%. Lide convertible bonds rose by more than 7%, and Weipai convertible bonds rose by more than 4%; Z-mode convertible bonds fell by nearly 3%, while Fuxin convertible bonds and Yinxin convertible bonds fell by nearly 2%.

Tik Tok bean bag concept stocks opened lower and went higher, three-dimensional communication rose daily, Zhejiang-Wenzhou Internet, Zhangyue Technology and Guangbo shares rose sharply.Look at the picture: The increased confidence of Japan's large-scale manufacturing industry indicates that the economic development is in line with the Bank of Japan's forecast. Before the Bank of Japan's policy meeting next week, the confidence of Japan's large-scale manufacturing industry has increased. According to the quarterly short-term report released by the Bank of Japan on Friday, the short-term survey index of Japan's large manufacturing industry rose slightly to 14 in December, with an estimated 13. The short-term survey index of large non-manufacturing industry decreased slightly from 34 to 33. Small businesses' confidence in manufacturing and service industries has also improved, although the outlook has slightly weakened or remained unchanged. The short-term report has attracted the attention of the Bank of Japan and is the last batch of major domestic data that will be carefully studied before the interest rate decision on December 19. This result shows that Japan's economic development is in line with the forecast of the Bank of Japan and is a condition for further interest rate hike. Compared with December, economists are more inclined to expect the Bank of Japan to take action in January next year, but still believe that the risk of raising interest rates next week is high.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)